Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by HighTide Therapeutics Inc.

HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
From HighTide Therapeutics Inc.
Via ACN Newswire
Tickers HTTIF
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes
From HighTide Therapeutics Inc.
Via ACN Newswire
Tickers HTTIF
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
From HighTide Therapeutics Inc.
Via ACN Newswire
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open
From HighTide Therapeutics Inc.
Via ACN Newswire
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
From HighTide Therapeutics Inc.
Via ACN Newswire
HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology
From HighTide Therapeutics Inc.
Via Business Wire
HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021
From HighTide Therapeutics Inc.
Via Business Wire
HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients
From HighTide Therapeutics Inc.
Via Business Wire
HighTide Therapeutics Announces the Presentation of Topline Results of Phase 2 Study of HTD1801 in PSC Patients at the International Liver Congress 2021
From HighTide Therapeutics Inc.
Via Business Wire
HighTide Announces NMPA Approval for HTD1801 Clinical Trial in China
From HighTide Therapeutics Inc.
Via Business Wire
HighTide to Present at the BofA Securities 2021 Health Care Conference
From HighTide Therapeutics Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.